Cellectis S.A. (CMVLF)

2.6000 0.0000 (0.00%) As of 02:49PM EDT. Market open.

Cellectis S.A.

8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Andre Choulika Ph.D.	Co-Founder, CEO & Director	876.6k	N/A	1965
Dr. David j. d. Sourdive Ph.D.	Deputy CEO, Executive VP of CMC & Manufacturing and Director	557.84k	N/A	1967
Valerie Cros	Principal Financial Officer & Principal Accounting Officer	N/A	N/A	N/A
Mr. Jean Charles Epinat	Chief Technological Officer	N/A	N/A	N/A
Dr. Philippe Duchateau Ph.D.	Chief Scientific Officer	N/A	N/A	1963
Mr. Stephan Reynier M.Sc.	Chief Regulatory & Pharmaceutical Compliance Officer	N/A	N/A	1969
Ms. Marie-Bleuenn Terrier	General Counsel & Secretary of the Board of Directors	N/A	N/A	1982
Pascalyne Wilson	Director of Communications	N/A	N/A	N/A
Ms. Kyung Nam-Wortman	Executive VP & Chief Human Resources Officer	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Corporate governance

Cellectis S.A.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 9; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.